TY - CONF
T1 - High level of adherence to osteoporosis prophylaxis medications in steroid-treated polymyalgia rheumatica (pmr)/giant cell arteritis (gca) patients
T2 - 7th Asia-Pacific Osteoporosis Conference
AU - Emamifar, Amir
AU - Ellingsen, Torkell Juulsgaard
AU - Hermann, Anne Pernille
AU - Hess, Søren
AU - Jensen Hansen, Inger Marie
AU - Thye-Rønn, Peter
PY - 2018
Y1 - 2018
N2 - Objectives: Adherence to the osteoporosis prophylaxis medications can play a significant role to prevent steroid-induced osteoporosis. The objective of this study was to evaluate the level of adherence to osteoporosis prophylaxis medications in newly diagnosed steroid-treated polymyalgia rheumatica (PMR)/giant cell arteritis (GCA) patients. Method: This is an ongoing prospective study. 37 consecutive pts. with newly diagnosed PMR/GCA were included in the study. The patients were requested to perform a total body DXA at time of diagnosis or shortly after. Hereafter, patients were contacted by nurses after a week of treatment initiation to evaluate the effect of treatment and to review the details. After 4 weeks of treatment with prednisolone, all included patients were interviewed about their compliance towards osteoporosis prophylaxis using a standardized questionnaire at first follow up visit. Patients were asked if they had remembered to take their prescribed medications. The standard treatment for prevention of osteoporosis was calcium (1200 mg/d) plus vitamin D (800 U/d) and 70 mg alendronate weekly (if T-score ≤−1). Results: Of 37 pts., 3 pts. were excluded from the study because of lack of interest or a change in the initial diagnosis. Statistical analyses were performed for the rest 34 pts. Results of DXA scan were available for 30 pts. Of all included pts. 61.8% were female and mean age (confidence interval) was 71 (69-74) y. 24 pts. had pure PMR symptoms, 2 pts. pure cranial GCA, 8 pts. with concurrent PMR and GCA. The cumulative prednisolone dose was 696.2 (516.9-1123.1) (median (interquartile range)). The mean of erythrocyte sedimentation rate 61.8 and C-reactive protein 44.9 at diagnosis decreased to 10.7 and 4.0, respectively, after 4 weeks of treatment. At time of diagnosis, 30% and 53.3% of pts. had osteoporosis (T-score ≤ -2.5) and osteopenia (-1≤ T-score
AB - Objectives: Adherence to the osteoporosis prophylaxis medications can play a significant role to prevent steroid-induced osteoporosis. The objective of this study was to evaluate the level of adherence to osteoporosis prophylaxis medications in newly diagnosed steroid-treated polymyalgia rheumatica (PMR)/giant cell arteritis (GCA) patients. Method: This is an ongoing prospective study. 37 consecutive pts. with newly diagnosed PMR/GCA were included in the study. The patients were requested to perform a total body DXA at time of diagnosis or shortly after. Hereafter, patients were contacted by nurses after a week of treatment initiation to evaluate the effect of treatment and to review the details. After 4 weeks of treatment with prednisolone, all included patients were interviewed about their compliance towards osteoporosis prophylaxis using a standardized questionnaire at first follow up visit. Patients were asked if they had remembered to take their prescribed medications. The standard treatment for prevention of osteoporosis was calcium (1200 mg/d) plus vitamin D (800 U/d) and 70 mg alendronate weekly (if T-score ≤−1). Results: Of 37 pts., 3 pts. were excluded from the study because of lack of interest or a change in the initial diagnosis. Statistical analyses were performed for the rest 34 pts. Results of DXA scan were available for 30 pts. Of all included pts. 61.8% were female and mean age (confidence interval) was 71 (69-74) y. 24 pts. had pure PMR symptoms, 2 pts. pure cranial GCA, 8 pts. with concurrent PMR and GCA. The cumulative prednisolone dose was 696.2 (516.9-1123.1) (median (interquartile range)). The mean of erythrocyte sedimentation rate 61.8 and C-reactive protein 44.9 at diagnosis decreased to 10.7 and 4.0, respectively, after 4 weeks of treatment. At time of diagnosis, 30% and 53.3% of pts. had osteoporosis (T-score ≤ -2.5) and osteopenia (-1≤ T-score
M3 - Paper
ER -